THROMBOTIC AND THROMBOEMBOLIC COMPLICATIONS IN SYSTEMIC VASCULITIS

Nowadays, there is no doubt about the relationship between immune inflammation and the development of thrombosis due to the similarity of many pathogenetic machanisms underlying both pathological processes. Systemic vasculitis, along with other immuno- mediated inflammatory diseases, represent one of the most clear examples of such interaction. Thrombotic complications remain one of the most serious and life-threatening conditions that occur in patients with autoimmune diseases, in particular systemic vasculitis. This serves as powerful stimulus for studing the problem of hypercoagulation, which often accompanies the course of systemic vasculitis. Of interest are thrombosis that occure both in the injury of large vessel and in the involvement of medium and small vessels in the pathological process. According to the literature, thrombotic and thromboembolic complications are most common in ANCA-associated vasculitis and Behçet’s disease. This review discusses current studies regarding features of clinical picture and mechanisms of thrombosis development in systemic vasculitis. Because of these studies it became clear that for some vasculitis a high frequency of both arterial and venous thrombosis is characteristic. At the same time, other vasculitis are accompanied by high risk of only venous thrombosis. Finally, thrombosis and thromboembolism are quite rare complications for some vasculitis. Among the presented mechanisms of thrombosis involvement, disruptions of the hemostasis are widely considered. For examples, the presents the results of researches, which is actively discussed the role of neutrophil extracellular traps and antiendothelial cell antibodies in the development on thrombotic complictions. Special attention is paid to the possible role of some disorders of hemostasis, such as polymorphism V coagulation factor G1691FA and prothrombin G20210A. To search for literature sources, the following queries were used: “vasculitis”, “thrombosis”, “neutrophil extracellular traps”, “ANCA-associated vasculitis”, “venous thrombosis”, “arterial thrombosis”, “Behçet’s disease”, “Takayasu arteritis”, “granulomatosis with polyangiitis”, “eosinophilic granulomatosis with polyangiitis”, “Mmicroscopic polyangiitis”, “Henoch–Schönlein purpura”, “Kawasaki disease”, “polyarteritis nodosa”, “giant cell arteritis”, “Buerger’s disease”. In addition, use similar requests in English. The search was carried out in PubMed.

vasculitis, thrombosis, neutrophil extracellular traps, ANCA-associated vasculitis, venous thrombosis, arterial thrombosis, Behçet’s disease, Takayasu arteritis, granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, microscopic polyangiitis, Henoch–Schönlein purpura, Kawasaki disease, polyarteritis nodosa, giant cell arteritis, Buerger’s disease

1. Desbois A.C., Wechsler B., Cluzel P. et al. Cardiovascular involvement in Behçet’s disease. Rev Med Interne 2014;35(2): 103–11. DOI: 10.1016/j.revmed.2013.12.002. PMID: 24434015.

2. Ly K.H., Liozon E., Dalmay F. et al. Venous thrombosis in patients with giant cell arteritis: Features and outcomes in a cohort study. Joint Bone Spine 2017;84(3):323–6. DOI: 10.1016/j.jbspin.2016.04.011. PMID: 27324606.

3. Hwang J., Kim S.J., Bang O.Y. et al. Ischemic stroke in Takayasu's arteritis: lesion patterns and possible mechanisms. J Clin Neurol 2012;8(2):109–15. DOI: 10.3988/jcn.2012.8.2.109. PMID: 22787494.

4. Jennette J.C. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol 2013;17(5):603–6. DOI: 10.1007/s10157-013-0869-6. PMID: 24072416.

5. Ames P.R., Margaglione M., Mackie S., Alves J.D. Eosinophilia and thrombophilia in churg strauss syndrome: a clinical and pathogenetic overview. Clin Appl Thromb Hemost 2010;16(6):628–36. DOI: 10.1177/1076029609348647. PMID: 19833618.

6. Weidner S., Hafezi-Rachti S., Rupprecht H.D. Thromboembolic events as a complication of antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum 2006;55(1):146–9. DOI: 10.1002/art.21704. PMID: 16463427.

7. Allenbach Y., Seror R., Pagnoux C. et al. High frequency of venous thromboembolic events in Churg–Strauss syndrome, Wegener’s granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis 2009;68(4):564–7. DOI: 10.1136/ard.2008.099051. PMID: 19015208.

8. Stassen P.M., Derks R.P., Kallenberg C.G., Stegeman C.A. Venous thromboembolism in ANCA-associated vasculitis incidenceand risk factors. Rheumatology 2008;47(4):530–4. DOI: 10.1093/rheumatology/ken035. PMID: 18356178.

9. Whyte A.F., Smith W.B., Sinkar S.N. et al. Clinical and laboratory characteristics of 19 patients with Churg-Strauss syndrome from a single South Australian centre. Intern Med J 2013;43(7):784-90. DOI: 10.1111/imj.12173. PMID: 23611179.

10. Faurschou M., Obel N., Baslund B. High risk of pulmonary embolism and deep venous thrombosis but not of stroke in granulomatosis with polyangiitis (Wegener's). Arthritis Care Res (Hoboken) 2014;66(12):1910–4. DOI: 10.1002/acr.22423. PMID: 25073637.

11. Morgan M.D., Turnbull J., Selamet U. et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. Arthritis Rheum 2009;60(11):3493–500. DOI: 10.1002/art.24957. PMID: 19877070.

12. Faurschou M., Mellemkjaer L., Soren- sen I.J. et al. Increased morbidity from ischemic heart disease in patients with Wegener’s granulomatosis. Arthritis Rheum 2009;60(4):1187–92. DOI: 10.1002/art.24386. PMID: 19333952.

13. Suppiah R., Judge A., Batra R. et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener’s granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken) 2011;63(4):588–96. DOI: 10.1002/acr.20433. PMID: 21452269.

14. Wang C., Chang D.Y., Chen M., Zhao M.H. HMGB1 contributes to glomerular endothelial cell injury in ANCA-associated vas culitis through enhancing endotheliumneutrophil interactions. J Cell Mol Med 2017;21(7):1351–60. DOI: 10.1111/jcmm.13065. PMID: 28181422.

15. Kambas K., Chrysanthopoulou A., Vassilopoulos D. et al. Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease. Ann Rheum Dis 2014;73(10):1854–63. DOI: 10.1136/annrheumdis-2013-203430. PMID: 23873874.

16. Legendre P., Régent A., Thiebault M. et al. Anti-endothelial cell antibodies in vasculitis: A systematic review. Autoimmun Rev 2017;16(2):146–53. DOI: 10.1016/j.autrev.2016.12.012. PMID: 27989761.

17. Cugno M., Marzano A.V., Lorini M. et al. Enhanced tissue factor expression by blood eosinophils from patients with hypereosinophilia: a possible link with thrombosis. PLoS One 2014;9(11):e111862. DOI: 10.1371/journal.pone.0111862. PMID: 25375118.

18. Hao J., Wang C., Gou S.J. et al. The association between anti-plasminogen antibodies and disease activity in ANCA-associated vasculitis. Rheumatology (Oxford) 2014;53(2):300–6. DOI: 10.1093/rheumatology/ket345. PMID: 24162033.

19. Hilhorst M., Winckers K., Wilde B. et al. Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission are hypercoagulable. J Rheumatol 2013;40(12):2042–6. DOI: 10.3899/jrheum.130200. PMID: 24128780.

20. Davatchi F., Shahram F., Chams-Davatchi C. et al. Behcet’s disease: from east to west. Clin Rheumatol 2010;29(8):823–33. DOI: 10.1007/s10067-010-1430-6. PMID: 20354748.

21. Saadoun D., Wechsler B. Behcet’s disease. Orphanet J Rare Dis 2012;7:20. DOI: 10.1186/1750-1172-7-20. PMID: 2249799.

22. Cakmak O.S., Seyahi E., Kantarci F. et al. Venous severity assessment in Behçet’s syndrome. Clin Exp Rheumatol 2010;28(60):139. PMID: 23009740.

23. Sarica-Kucukoglu R., Akdag-Kose A., Kayabal I.M. et al. Vascular involvement in Behcet’s disease: a retrospective analysis of 2319 cases. Int J Dermatol 2006;45(8):919–21. DOI: 10.1111/j.1365-4632.2006.02832.x. PMID: 16911374.

24. Calamia K.T., Schirmer M., Melikoglu M. Major vessel involvement in Behcet’s disease: an update. Curr Opin Rheumatol 2011;23(1):24–31. DOI: 10.1097/BOR.0b013e3283410088. PMID: 21124084.

25. Tunc R., Saip S., Siva A., Yazici H. Cerebral venous thrombosis is associated with major vessel disease in BS’s syndrome. Ann Rheum Dis 2004;63(12):1693–4. DOI: 10.1136/ard.2003.018515. PMID: 15547099.

26. Saadoun D., Wechsler B., Resche-Rigon M. et al. Cerebral venous thrombosis in Behcet’s disease. Arthritis Rheum 2009;61(4):518–26. DOI: 10.1002/art.24393. PMID: 19333987.

27. Saadoun D., Wechsler B., Desseaux K. et al. Mortality in Behcet’s disease. Arthritis Rheum 2010;62(9):2806–12. DOI: 10.1002/art.27568. PMID: 20496419.

28. Desbois A.C., Wechsler B., Resche-Rigon M. et al. Immunosuppressants reduce venous thrombosis relapse in Behcet's disease. Arthritis Rheum 2012;64(8):2753–60. DOI: 10.1002/art.34450. PMID: 22354392.

29. Düzgün N., Ateş A., Aydintuğ O.T. et al. Characteristics of vascular involvement in Behçet's disease. Scand J Rheumatol 2006;35(1):65–8. DOI: 10.1080/03009740500255761. PMID: 16467046.

30. Ceyran H., Akcali Y., Kahraman C. Surgical treatment of vasculo-Behcet’s disease. A review of patients with concomitant multiple aneurysms and venous lesions. Vasa 2003;32(3):149–53. DOI: 10.1024/0301-1526.32.3.149. PMID: 14524035.

31. Mogulkoc N., Burgess M.I., Bishop P.W. Intracardiac thrombus in Behcet’s disease: a systematic review. Chest 2000;118(2):479–87. PMID:10936144.

32. Silvestri E., Cenci C., Della Bella C. et al. Behçet’s syndrome: from pathogenesis to treatment. Milan: Springer-Verlag, 2014.

33. Engelmann B., Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013;13(1):3 4–45. DOI: 10.1038/nri3345. PMID: 23222502.

34. Butta N.V., Fernández-Bello I., LópezLongo F.J. et al. Endothelial dysfunction and altered coagulation as mediators of thromboembolism in Behçet disease. Semin Thromb Hemost 2015;41(6):621–8. DOI: 10.1055/s-0035-1556727. PMID: 26276934.

35. Kose O. Development of Immunopathogenesis Strategies to Treat Behcet’s Disease. Patholog Res Int 2012;2012:261989. DOI: 10.1155/2012/261989. PMID: 22550612.

36. Neves F.S., Spiller F. Possible mechanisms of neutrophil activation in Behçet’s disease. Int Immunopharmacol 2013;17(4):1206–10. DOI: 10.1016/j.intimp.2013.07.017. PMID: 23973446.

37. La Regina M., Orlandini F., Prisco D., Dentali F. Homocysteine in vascular Behcet disease: a meta-analysis. Arterioscler Thromb Vasc Biol 2010;30(10):2067–74. DOI: 10.1161/ATVBAHA.110.207068. PMID: 20634474.

38. Jennette J.C., Falk R.J., Bacon P.A. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65(1):1–11. DOI: 10.1002/art.37715. PMID: 23045170.

39. Avina-Zubieta J.A., Bhole V.M., Amiri N. et al. The risk of deep venous thrombosis and pulmonary embolism in giant cell arteritis: a general population-based study. Ann Rheum Dis 2016;75(1):148–54. DOI: 10.1136/annrheumdis-2014-205665. PMID: 25265937.

40. Zoller B., Li X., Sundquist J. et al. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 2012;379(9812):244–9. DOI: 10.1016/S0140-6736(11)61306-8. PMID: 22119579.

41. Tomasson G., Peloquin C., Mohammad A. et al. Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study. Ann Intern Med 2014;160(2):73–80. DOI: 10.7326/M123046. PMID: 24592492.

42. Gonzalez-Gay M.A., Pineiro A., GomezGigirey A. et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore) 2004;83(6):342–7. PMID: 15525846.

43. Gonzalez-Gay M.A., Vazquez-Rodriguez T.R., Gomez-Acebo I. et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore) 2009;88(4):227–35. DOI: 10.1097/MD.0b013e3181af4518. PMID: 19593228.

44. Samson M., Jacquin A., Audia S. et al. Stroke associated with giant cell arteritis: a population-based study. J Neurol Neurosurg Psychiatry 2015;86(2):216–21. DOI: 10.1136/jnnp-2014-307614. PMID: 24780954.

45. Udayakumar P.D., Chandran A.K., Crowson C.S. et al. Cardiovascular risk and acute coronary syndrome in giant cell arteritis: a population based retrospective cohort study. Arthritis Care Res (Hoboken) 2015;67(3):396–402. DOI: 10.1002/acr.22416. PMID: 25074472.

46. Gonzalez-Gay M.A., Garcia-Porrua C., Gonzalez-Juanatey C. et al. Biopsy-proven giant cell arteritis patients with coronary artery disease have increased risk of aortic aneurysmal disease and arterial thrombosis. Clin Exp Rheumatol 2013;31(1 Suppl 75):S94. PMID: 23463922.

47. Hwang J., Kim S.J., Bang O.Y. et al. Ischemic stroke in Takayasu’s arteritis: lesion patterns and possible mechanisms. J Clin Neurol 2012;8(2):109–15. DOI: 10.3988/jcn.2012.8.2.109. PMID: 22787494.

48. Ohta T., Ishioashi H., Hosaka M., Sugimoto I. Clinical and social consequences of Buerger disease. J Vasc Surg 2004;39(1):176–80. DOI: 10.1016/j.jvs.2003.08.006. PMID: 14718836.

49. Adar R., Papa M.Z., Halpern Z. et al. Cellular sensitivity to collagen in thromboangiitis obliterans. N Engl J Med 1983;308(19):1113–6. DOI: 10.1056/NEJM198305123081901. PMID: 6835334.

50. Klein-Weigel P.F., Bimmler M., Hempel P. et al. G-protein coupled receptor auto-antibodies in thromboangiitis obliterans (Buerger’s disease) and their removal by immunoadsorption. Vasa 2014;43(5): 347–52. DOI: 10.1024/0301-1526/a000372. PMID: 25147011.

51. Małecki R., Kluz J., Przeździecka-Dołyk J. et al. The Pathogenesis and Diagnosis of Thromboangiitis obliterans: Is It Still a Mystery? Adv Clin Exp Med 2015;24(6):1085–97. DOI: 10.17219/ acem/33322. PMID: 26771983.

52. Li L., Zhang J., Zhang Y., Ji H. Thrombosis warning in children suffering from henoch-schonlein purpura. Indian J Dermatol 2013;58(5):409. DOI: 10.4103/0019-5154.117349. PMID: 24082216.

53. Kurotobi S., Kawakami N., Honda A. et al. Impaired vascular endothelium-dependent relaxation in Henoch-Schönlein purpura. Pediatr Nephrol 2004;19(2):138–43. DOI: 10.1007/s00467-003-1335-6. PMID: 14685839.

54. Yilmaz D., Kavakli K., Ozkayin N. The elevated markers of hypercoagulability in children with Henoch-Schönlein purpura. Pediatr Hematol Oncol 2005;22(1):41–8. PMID: 15770830.

55. Sanchez-Manubens J., Bou R., Anton J. Diagnosis and classification of Kawasaki disease. J Autoimmun 2014;48–49:113–7. DOI: 10.1016/j.jaut.2014.01.010. PMID: 24485156.

56. Adler A.C., Kodavatiganti R. Kawasaki disease and giant coronary artery aneurysms: the role of echocardiography from diagnosis through follow-up. Echocardiography 2016;33(8):1245–50. DOI: 10.1111/echo.13271. PMID: 27357568.

57. Bachlava E., Loukopoulou S., Karanasios E. et al. Management of coronary artery aneurysms using abciximab in children with Kawasaki disease. Int J Cardiol 2016;220:65–9. DOI: 10.1016/j. ijcard.2016.06.062 PMID: 27372045.